A total of 1463 patients, including 929 primary GCs and 534 primary GEJ adenocarcinomas, was retrospectively analyzed for HER2 overexpression by immunohistochemistry (IHC). The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.